Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
BAC Bank of America Corp
FIVN Five9 Inc
IPOF Social Capital Hedosophia Holdings Corp VI
NIO NIO Inc
NRT North European Oil Royalty Trust
JNJ Johnson & Johnson
STAG STAG Industrial Inc
TM Toyota Motor Corp
HSIC Henry Schein Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Price
Delayed
$1.97
Day's Change
-0.05 (-2.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.06
Day's Low
1.95
Volume
(Light)

Today's volume of 4,381,275 shares is on pace to be much lighter than CRBP's 10-day average volume of 13,385,254 shares.

4,381,275
Latest Earnings Met Consensus (Q3 ending 09/2020)Next Earnings Announcement
Q3
Announced November 9, 2020
-$0.42Q3 Estimate range
of 7 analysts
-$0.52 to -$0.33Q4 Earnings
will announce
(Unconfirmed) March 12, 2021

Quarterly Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

CRBP's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.